일반의약품 진통제 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the over-the-counter analgesics market size is expected to grow from USD 30.16 billion in 2025 to USD 31.37 billion in 2026 and is forecast to reach USD 37.93 billion by 2031 at 3.87% CAGR over 2026-2031.

This report is Segmented by Drug Type (Acetaminophen, Non-Steroidal Anti-Inflammatory Drugs, Salicylates, Other Analgesics), Formulation (Oral Formulations, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Over-the-counter (OTC) Analgesics Market Trends and Insights

Increasing Demand for Topical Analgesics

Topical gels, patches, and sprays appeal to users who seek localized relief and prefer to avoid hepatic metabolism. European registrations for topical NSAIDs increased by 22% year-over-year in 2025, reflecting endorsements from regulators and employers. Hisamitsu's Salonpas patch posted JPY 38 billion (USD 255 million) fiscal-year sales, helped by wider U.S. retail placement. Employers are steering workers' compensation cases toward non-systemic therapy to limit downtime. Microneedle patches in early trials promise therapeutic plasma levels with far lower systemic exposure. Together, these factors underpin the segment's sustained momentum.

Growing Geriatric Population & Musculoskeletal Disease Burden

The world is expected to have 1.4 billion people aged 60 and above by 2030, while the prevalence of osteoarthritis is projected to reach 528 million cases by 2025. Japan reports that seniors spend 14% more per capita on OTC analgesics than adults under 50. India's elderly-care program subsidizes NSAIDs in rural clinics, adding millions of new users. Dysphagia, present in roughly 30% of nursing-home residents, tilts demand toward patches, gels, or melt-in-mouth films. Collectively, demographic and disease trends create a durable consumption base.

Drug Tolerance, Dependence, Misuse & Abuse Risks

Short-pack regulations are tightening. The UK limited codeine-containing packs to a 3-day supply in 2024 after data showed 8% of chronic users met substance-use-disorder criteria. U.S. emergency departments recorded 56,000 acetaminophen-related visits in 2024. The FDA plans to implement a standardized Drug Facts label for acetaminophen, which is expected to cost the industry an estimated USD 120 million. Retailers, such as CVS, piloted point-of-sale limits on high-dose ibuprofen in 2025. These measures signal rising scrutiny that could temper demand for OTC products.

Other drivers and restraints analyzed in the detailed report include:

1. Cost-Efficiency and Convenience of OTC Pain Medicines
2. Rapid Expansion of E-Commerce & Online Pharmacies
3. Hepatotoxicity and GI / CV Risks

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Non-steroidal anti-inflammatory drugs (NSAIDs) accounted for 38.61% of the over-the-counter analgesics market share in 2025, driven by their broad efficacy in treating inflammatory pain. Salicylates, however, are expected to grow at 6.06% annually through 2031, outpacing overall growth as low-dose aspirin anchors chronic preventive use and topical methyl salicylate addresses localized pain needs. Aspirin's low unit cost keeps it competitive in price-sensitive economies. Sun Pharmaceutical's 75 mg aspirin plus vitamin D line earned INR 320 million (USD 3.8 million) in its first six months. The over-the-counter analgesics market size for salicylates is projected to rise steadily through both cardiovascular and pain pathways. NSAIDs face internal segmentation, with ibuprofen dominating acute use and naproxen gaining in chronic cohorts. Acetaminophen performance is plateauing amid hepatotoxicity warnings, though it remains preferred for patients with GI contraindications to NSAIDs.

Salicylates also benefit from regulatory clarity. The FDA cleared a more potent diclofenac gel for OTC use in 2024, intensifying competition within NSAIDs. Aspirin offers the lowest cost per dose, making it essential in India and Brazil. Growing wellness interest supports capsaicin and menthol products within "Other Analgesics," yet growth there remains moderate. Future momentum will hinge on innovation that differentiates delivery and mitigates safety concerns.

Complete Report Scope:

• By Drug Type
  • Acetaminophen
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Salicylates
  • Other Analgesics
• By Formulation
  • Oral Formulations
  • Topical Formulations
    • Creams & Gels
    • Sprays & Roll-ons
    • Transdermal Patches
  • Dissolvable / Fast-melt Strips
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies & E-commerce Platforms
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 39.24% of the revenue in the over-the-counter analgesics market in 2025. Growth moderates as opioid-reduction gains level off and generic competition compresses pricing. Canada's planned reclassification of low-dose codeine will steer CAD 85 million (USD 63 million) toward non-codeine OTC products. Mexico is growing faster, driven by pharmacy chain consolidation and a 2024 rule that empowers pharmacists to recommend analgesics without a physician's visit.

Asia-Pacific is forecast to deliver a 7.53% CAGR to 2031. India's OTC switch for select NSAIDs adds roughly 180 million potential users. China's online analgesic sales jumped 41% in 2025, thanks to Alibaba Health and JD Health, which were aided by provincial pilots that eliminated in-person verification. Japan's super-aged population spends JPY 4,200 (USD 28) per capita on OTC pain products. Australia shifted higher-strength ibuprofen to pharmacy-only OTC in 2024, moving AUD 32 million (USD 21 million) from prescription channels.

Europe sees slower expansion amid strict pack-size limits. Germany's ibuprofen sales declined 3.2% in 2025 following the introduction of cardiovascular warning labels, while topical diclofenac sales increased 11%. France maintains pharmacist gatekeeping that curbs impulse purchases. Middle East and Africa remain small but gain from Saudi Arabia's expanded dispensing rights; the Saudi Food and Drug Authority cleared 23 new OTC registrations in 2024. South America's leading market, Brazil, saw private-label share reach 28% in 2025 amid economic headwinds.

1. Bayer
2. Boehringer Ingelheim
3. Cipla
4. Dr. Reddy's Laboratories
5. Endo International
6. GlaxoSmithKline
7. Haleon PLC
8. Hisamitsu Pharmaceutical
9. Johnson & Johnson
10. Mankind Pharma Ltd.
11. Novartis
12. Perrigo Company
13. Pfizer
14. PGT Healthcare LLP
15. Reckitt Benckiser Group
16. Sanofi
17. Sun Pharmaceuticals Industries
18. Taisho Pharmaceutical Holdings Co., Ltd.
19. Teva Pharmaceutical Industries
20. Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Demand for Topical Analgesics
  • 4.2.2 Growing Geriatric Population & Musculoskeletal Disease Burden
  • 4.2.3 Cost-Efficiency and Convenience of OTC Pain Medicines
  • 4.2.4 Rapid Expansion of E-Commerce & Online Pharmacies
  • 4.2.5 Opioid-Reduction Initiatives Accelerating Non-Opioid OTC Uptake
  • 4.2.6 Breakthrough Transdermal & Fast-Dissolve Delivery Technologies
• 4.3 Market Restraints
  • 4.3.1 Drug Tolerance, Dependence, Misuse & Abuse Risks
  • 4.3.2 Hepatotoxicity and GI / CV Risks
  • 4.3.3 Volatile Menthol / API Prices Squeezing Manufacturer Margins
  • 4.3.4 Emerging Non-Pharma Pain Devices Diverting Consumer Spend
• 4.4 Regulatory Landscape
• 4.5 Technological Outlook
• 4.6 Porter's Five Forces Analysis
  • 4.6.1 Threat of New Entrants
  • 4.6.2 Bargaining Power of Buyers
  • 4.6.3 Bargaining Power of Suppliers
  • 4.6.4 Threat of Substitutes
  • 4.6.5 Competitive Rivalry

5 Market Size & Growth Forecasts

• 5.1 By Drug Type
  • 5.1.1 Acetaminophen
  • 5.1.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.1.3 Salicylates
  • 5.1.4 Other Analgesics
• 5.2 By Formulation
  • 5.2.1 Oral Formulations
  • 5.2.2 Topical Formulations
    • 5.2.2.1 Creams & Gels
    • 5.2.2.2 Sprays & Roll-ons
    • 5.2.2.3 Transdermal Patches
  • 5.2.3 Dissolvable / Fast-melt Strips
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies & Drug Stores
  • 5.3.3 Online Pharmacies & E-commerce Platforms
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market-level Overview, Core Segments, Financials, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
  • 6.3.1 Bayer AG
  • 6.3.2 Boehringer Ingelheim International GmbH
  • 6.3.3 Cipla Ltd.
  • 6.3.4 Dr. Reddy's Laboratories Ltd.
  • 6.3.5 Endo International PLC
  • 6.3.6 GlaxoSmithKline plc
  • 6.3.7 Haleon PLC
  • 6.3.8 Hisamitsu Pharmaceutical Co., Inc.
  • 6.3.9 Johnson & Johnson
  • 6.3.10 Mankind Pharma Ltd.
  • 6.3.11 Novartis AG
  • 6.3.12 Perrigo Company plc
  • 6.3.13 Pfizer Inc.
  • 6.3.14 PGT Healthcare LLP
  • 6.3.15 Reckitt Benckiser Group PLC
  • 6.3.16 Sanofi SA
  • 6.3.17 Sun Pharmaceutical Industries Ltd.
  • 6.3.18 Taisho Pharmaceutical Holdings Co., Ltd.
  • 6.3.19 Teva Pharmaceutical Industries Ltd.
  • 6.3.20 Viatris Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment